Alphabet's isomorphic labs eyes $40 billion valuation in new funding talks

Isomorphic Labs, an AI-driven drug discovery startup originating from Alphabet Inc.'s Google DeepMind, is currently engaged in preliminary discussions to secure fresh capital at a valuation of at least $40 billion, as reported by individuals with knowledge of the initiative. The company, which leverages artificial intelligence to accelerate pharmaceutical research, is positioning itself for significant investment interest. The talks, which are in the early stages, reflect growing confidence in the startup's potential to transform the drug development landscape. With the current date being 2026-10-08, the valuation target aligns with the company's trajectory in the current year. The potential funding round underscores the increasing importance of AI in biotechnology and pharmaceutical innovation. The development highlights the broader trend of tech giants investing in life sciences through their subsidiaries and ventures.